Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
about
Immunotherapy of systemic sclerosisPathogenesis of primary sclerosing cholangitis and advances in diagnosis and managementFibrotic and sclerotic manifestations of chronic graft-versus-host diseaseTransport mechanisms and their pathology-induced regulation govern tyrosine kinase inhibitor delivery in rheumatoid arthritisDuctular reaction correlates with fibrogenesis but does not contribute to liver regeneration in experimental fibrosis models.Fibrillin assemblies: extracellular determinants of tissue formation and fibrosisCombined taurine, epigallocatechin gallate and genistein therapy reduces HSC-T6 cell proliferation and modulates the expression of fibrogenic factors.Protein kinase Cδ and c-Abl kinase are required for transforming growth factor β induction of endothelial-mesenchymal transition in vitroElevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblastsPulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.Different anti-remodeling effect of nilotinib and fluticasone in a chronic asthma model.The tyrosine kinase inhibitor dasatinib reduces lung inflammation and remodelling in experimental allergic asthma.Epigenetic modifications: novel therapeutic strategies for systemic sclerosis?Specific delivery of kinase inhibitors in nonmalignant and malignant diseases.More than skin deep? Emerging therapies for chronic cutaneous GVHD.Diverse origins of the myofibroblast—implications for kidney fibrosis.The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrenceMultiparameter Analysis of Off-Target Effects of Dasatinib on Bone Homeostasis in Patients With Newly Diagnosed Chronic Myelogenous Leukemia.Potent inhibition of TGF-β signaling pathway regulator Abl: potential therapeutics for hepatic fibrosis.The vascular microenvironment and systemic sclerosis.Constitutive activation of c-Abl/protein kinase C-δ/Fli1 pathway in dermal fibroblasts derived from patients with localized scleroderma.Antifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trial.Role of tyrosine kinase inhibition with imatinib in an encapsulating peritoneal sclerosis rat model.Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib.Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.
P2860
Q24634395-F5BA718D-E3FA-41C9-AED2-164C4AE786F7Q27015831-949F7D05-FDDC-4F61-83F0-BEAFDB41CF66Q27024147-4ED3DDF6-7C78-47D2-A140-C403B6E041C6Q28484465-135EEC20-607E-4DAE-8AFA-043A28A80861Q33605760-31B8396B-6BFA-4C11-B075-4849957FAD5DQ34447925-CC689C80-264B-4705-89FB-DE3FA44206E3Q35017823-807C6465-B554-4DC1-B92D-5AE29BC9D271Q35100214-E3FDF5F3-8391-4849-8D98-7FE7B53847C5Q35142313-2E016A36-8135-4D09-9EAB-795ADBBEA154Q36795578-298362BE-300F-42D7-B8D0-07198911E403Q37392438-C0A7142B-354B-4D65-BF87-6442BD378C79Q37686313-2C841DD0-0C89-4C93-A0DB-023F1E515621Q37905791-A43A3192-E707-42B6-B33E-4FDB20656DD3Q37960141-2AEAE8FE-9C7F-4A4C-9CED-DC3FEF916A49Q38032083-3D0CEBFF-2EF1-4071-8242-B5EAE9176E17Q38316792-2D68BA2E-D8E5-49B2-8A2C-B11FBA6D589BQ38536374-8013EB0E-DEA3-43BD-93E9-F1C6F33C7250Q40397359-ABF0811D-5408-44E2-9B50-FAFA7841AA29Q41651767-C207111D-4DF3-49AE-9D21-9E991B806725Q41863950-B7FCEA67-E287-4065-AA2A-AC8FD01E683FQ44878948-3D59217F-9B77-416B-9E38-E3E01EF0A979Q45761415-FC943A09-532C-4BF4-9CC2-9797FF7ADECDQ53117214-08E8CADC-6AD8-4D23-BD7E-E0C8BFD46D40Q53371980-5EDD4CD1-C8E6-4774-8340-C899A28C7E06Q54573262-2D71A892-5415-499D-8DCA-8DDD4CF2DFF5
P2860
Tyrosine kinase inhibitors for the treatment of fibrotic diseases such as systemic sclerosis: towards molecular targeted therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@en
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@nl
type
label
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@en
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@nl
prefLabel
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@en
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@nl
P356
P1476
Tyrosine kinase inhibitors for ...... molecular targeted therapies.
@en
P2093
J H W Distler
P304
P356
10.1136/ARD.2009.120196
P407
P478
69 Suppl 1
P577
2010-01-01T00:00:00Z